Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* History of heartburn (defined as a burning sensation in the retrosternal area of the chest) that is refractory to antisecretory medications~* Initial GERD-HRQL:~  * Total score must be at least 6 and at least one of the six heartburn questions must be scored at least 2~* GERD-HRQL after two weeks of treatment with omeprazole:~  * Total score must be \>50% of the initial GERD-HRQL score and at least one of the six heartburn questions must be scored at least 2~* Either or both of the following by baseline esophageal pH/multichannel intraluminal impedance (MII) monitoring in patients on omeprazole 20 mg two times a day (BID):~  * Positive symptom association probability (SAP) (\>95%) for acid reflux, non-acid reflux or all reflux.~ * Abnormal acid reflux (esophageal pH\<4 for at least 4.2% of the 24-hour monitoring period)~Exclusion Criteria:~* Patients who do not have heartburn, defined as a burning sensation in the chest~* Patients unwilling or unable to provide informed consent~* Pregnancy or women unwilling to use effective contraception~* Age \<18 or \>70 years~* History of surgery on the stomach or esophagus~* History of seizure disorder~* History of heart block~* Allergy to or previous inability to tolerate study medications (omeprazole, baclofen, desipramine)~* Esophageal varices~* Cirrhosis~* Co-morbidity of sufficient severity to preclude elective surgery (e.g. pulmonary, cardiac, renal, liver disease)~* History of disorders that can cause medically-refractory GERD symptoms (eosinophilic esophagitis, neoplasms of the upper gastrointestinal tract, gastroparesis, achalasia)~* Myocardial infarction within the past 6 months~* History of schizophrenia~* Current use of clopidogrel~* Patients who have a contraindication to omeprazole or baclofen or who require therapy with a medication that has a clinically important drug interaction with omeprazole or baclofen.~* Patients who, in the judgment of the PI, are not suitable candidates for therapy with a study medication (omeprazole, baclofen, desipramine)~* Initial GERD-HRQL score: Total score \<6 and/or all heartburn scores \<2~* Inability to tolerate omeprazole during the 2-week treatment phase (before randomization)~* GERD-HRQL after two weeks of treatment with omeprazole: Total score less than or equal to 50% of initial GERD-HRQL score and/or all heartburn scores \<2~* Laboratory abnormalities including:~  * Platelet count \<100,000~ * international normalized ratio (INR) \>1.5 (off anticoagulants)~ * Serum creatinine \>2.0 mg per deciliter~* Endoscopic abnormalities including:~  * Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis~ * Active ulceration of the esophagus that is not due to reflux esophagitis~ * Candida esophagitis~ * Esophageal varices~ * Active ulceration of the stomach and/or duodenum~ * Neoplasm of the esophagus, stomach or duodenum~ * Gastric outlet obstruction~ * Eosinophilic esophagitis at least (15 eosinophils per high power field in any esophageal biopsy specimen)~* Manometric abnormalities including:~  * Achalasia~ * Complete aperistalsis~* Negative SAP ( 95%) for acid reflux, non-acid reflux and all reflux on baseline combined esophageal pH/MII monitoring and normal acid reflux (esophageal pH\<4 for \<4.2% of the 24-hour monitoring period)~* Study surgeon identifies a contraindication to laparoscopic Nissen fundoplication~* Morbid obesity (BMI at least 40)~* Large paraesophageal hernia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Medical Treatment Group (Type: OTHER): Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
- Surgical Treatment Group (Type: OTHER): Laparoscopic nissen fundoplications
- Placebo Medical Treatment Group (Type: OTHER): Omeprazole + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).